Erythropoietin Human Recombinant
Genital Neoplasms, Female
AmgenPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 89/ 100
Competitive context
11 Active assets in the Genital Neoplasms, Female cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Wenjun Cheng | Phase 3 | BB |
Inno-206 Amgen | Phase 3 | BB |
(+)-VINCRISTINE GlaxoSmithKline | Phase 2 | B |
Cyclophosphamide Sheba Medical Center | Phase 2 | B |
Irinotecan GlaxoSmithKline | Phase 2 | B |
View all 18 →
Same molecule, other indications
Erythropoietin Human Recombinant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →